Abstract 10013: PRDs Are Multifunctional Oral Inhibitors of PCSK9 and ACAT2

Introduction and Hypothesis: PCSK9-inhibition reduces the residual cardiovascular risk associated with LDL-cholesterol (LDL-C), but the wide-spread use of the antibody-based therapies is affected b...